TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Cilcare has established Cilcare K.K. in Tokyo, extending the French auditory biopharmaceutical company’s presence into Japan. Aurore Marie, who helped set up its U.S. operations, will lead the subsidiary as the company seeks to build on existing Japanese partnerships and develop activity across Asia-Pacific.
French auditory biopharmaceutical company Cilcare has established Cilcare K.K., a subsidiary based in Tokyo, and named Aurore Marie general manager for Japan and Asia. The move gives the Montpellier-headquartered company a local base in Japan as it seeks to expand its hearing-health work and partnerships across the Asia-Pacific region.
Cilcare said the Tokyo subsidiary is intended to build on more than a decade of engagement with Japanese universities, partners and hearing-health experts. The company says the local team will help it develop partnerships across Asia-Pacific and link regional stakeholders with its wider pharmaceutical and biotechnology network. The report does not detail the subsidiary’s staffing, operating budget or specific launch schedule.
The expansion follows a 2024 strategic partnership with Shionogi covering the co-development and commercialization of Cilcare programs CIL001 and CIL003. The source describes that agreement as evidence of existing activity in Japan; it does not report new development or regulatory milestones for either program as part of the subsidiary announcement.
Marie previously played a central role in establishing Cilcare’s presence in Boston, according to the company. Cilcare’s work includes auditory-science research and Synapsound AI, which the company describes as a platform for identifying auditory biomarkers and supporting earlier detection and characterization of neurological diseases. These are descriptions of the company’s activities and intended uses, not evidence in this announcement of clinical outcomes or product approvals.
A Local Base for Regional Partnerships
A Tokyo office gives Cilcare a dedicated presence in Japan rather than relying solely on relationships managed from Europe or the United States. Local leadership may make it easier for the company to coordinate with Japanese research institutions and commercial partners, while providing a base for outreach elsewhere in Asia-Pacific. The announcement signals an organizational expansion; it does not itself establish that new therapies, trials or commercial agreements have been launched.
The move is relevant to hearing-health researchers and industry partners because Cilcare is positioning its auditory-science portfolio for a region where it says it sees growth opportunities. Japan’s aging population and policy attention to prevention and healthy aging form part of the company’s rationale. The practical effects will depend on partnerships and research activity that develop after the office opens.
As an affiliate, we earn on qualifying purchases.
Cilcare’s Earlier Japan and U.S. Moves
Cilcare is headquartered in Montpellier, France, and has expanded its operations into the United States. The Tokyo subsidiary adds a second overseas base to that footprint, according to the source report. The company says its international work includes more than 350 collaborative projects in auditory science; that figure is company-reported and is not broken down by country or project type in the available material.
The Japanese expansion follows years of engagement with local academic and industry stakeholders, as well as the 2024 Shionogi partnership. Cilcare also acknowledged support from organizations including Business France, CCIFJ, the Enterprise Europe Network, the Occitanie Region and JETRO. The source does not specify the form or value of each organization’s support.
The broader public-health rationale includes research linking hearing loss with dementia risk. The source report refers to the 2024 Lancet Commission in that context. That background helps explain why hearing health is receiving attention, but it does not establish that Cilcare’s programs prevent dementia or treat it.
““Having a local team in Tokyo positions us to capture the significant opportunities ahead in hearing health.””
— Celia Belline, Cilcare CEO and co-founder, in a company release
As an affiliate, we earn on qualifying purchases.
Operations and Milestones Still Unspecified
The announcement does not state when the subsidiary began operations, how many people it will employ or how much Cilcare plans to invest in Japan. It also gives no timetable for new regional partnerships, clinical trials, product launches or regulatory submissions. The status and next milestones of CIL001 and CIL003 are not updated in the material.
Cilcare’s stated aims for Synapsound AI and its broader hearing-health work should be distinguished from demonstrated results: the source provides no new clinical data, approval decisions or commercial targets tied to the Tokyo office. The scale and pace of the company’s Asia-Pacific expansion therefore remain to be seen.
auditory biomarker detection tools
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Partnerships Will Test the Expansion
The next visible developments are likely to be announcements about the Tokyo team’s activities, regional collaborations or progress on existing programs. Cilcare has not provided dates for those milestones in the source report. Updates on its work with Shionogi or on clinical research would help clarify how the new office supports the company’s plans.
For now, the confirmed step is organizational: Cilcare has created a Japanese subsidiary and appointed a leader for its Japan and Asia operations. Whether that presence leads to new research, commercial arrangements or broader regional operations will depend on decisions and results not yet disclosed.
As an affiliate, we earn on qualifying purchases.
Key Questions
What has Cilcare announced?
Cilcare said it established Cilcare K.K., a subsidiary based in Tokyo, to support its presence in Japan and planned activity across Asia-Pacific.
Who will lead the Tokyo subsidiary?
Aurore Marie has been named general manager for Japan and Asia. The source says she previously played a central role in establishing Cilcare’s U.S. presence in Boston.
Does the announcement include a new deal with Shionogi?
No new Shionogi agreement is described. The report points to a 2024 strategic partnership covering co-development and commercialization of CIL001 and CIL003 as existing Japanese activity.
What is not yet known about the subsidiary?
The source does not give the office’s staffing, investment, operating timetable or schedule for new trials and partnerships. It also does not announce new clinical results or regulatory approvals.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
